Literature DB >> 3069935

Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy.

A Mimran1, A Insua, J Ribstein, L Monnier, J Bringer, J Mirouze.   

Abstract

Microalbuminuria is a reliable predictor of the eventual development of overt diabetic nephropathy and blood pressure is known to accelerate the course of this nephropathy. In the present studies, the effect of a 6-week treatment by placebo (n = 7), nifedipine (n = 7) and captopril (n = 8) on renal function and urinary excretion of albumin (UAE) was investigated in normotensive, insulin-dependent, diabetic patients with incipient nephropathy (UAE greater than 15 micrograms/min). No change in arterial pressure, renal function or UAE was observed in the placebo group. In response to captopril and nifedipine, mean arterial pressure decreased slightly and similarly in both groups. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) increased to a similar extent in the nifedipine group, thus resulting in no change in filtration fraction (FF). In response to captopril, GFR was unchanged whilst ERPF increased; as a consequence FF decreased. Opposite changes in UAE were observed in response to the two treatments; UAE decreased by 40% in the captopril group and by 40% in nifedipine-treated patients. These results indicate that intrarenal changes may be crucial with respect to the effect of therapy on UAE. It is suggested that only agents which reduce FF and probably intraglomerular capillary pressure, such as converting enzyme inhibitors, alter UAE and may possibly interfere with the course of incipient diabetic nephropathy in normotensive patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069935     DOI: 10.1097/00004872-198811000-00011

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.

Authors:  O Samuelsson; T Hedner; S Ljungman; H Herlitz; B Widgren; K Pennert
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

3.  Microalbuminuria in systemic sclerosis.

Authors:  A Dawnay; A G Wilson; E Lamb; J D Kirby; W R Cattell
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

Review 4.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 5.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 6.  Renoprotective role of ACE inhibitors in diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Heart J       Date:  1994-09

7.  Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.

Authors:  A J Apperloo; D de Zeeuw; H E Sluiter; P E de Jong
Journal:  BMJ       Date:  1991-10-05

8.  Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients.

Authors:  C Ferrier; P Ferrari; P Weidmann; U Keller; C Beretta-Piccoli; W F Riesen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  Renal long-term effects of calcium antagonist treatment in patients with diabetes mellitus.

Authors:  E Jungmann; K H Usadel
Journal:  Clin Investig       Date:  1992-10

Review 10.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.